Delivery Order SPE2DB25D2204-SPE2DB25FTGAM

Award Date 2/7/25
Potential Completion Date 2/10/25
Potential Value $8.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,948.40 firm fixed-price delivery order is for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML medical products. The contract has an ultimate completion date of October 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $55,533.78, is a delivery order for the medical product "ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML". The award has an ultimate completion date of January 16, 2025 and is a firm fixed price contract. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,586.44 firm fixed-price delivery order contract is for the supply of "ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML" medical products. The contract has an ultimate completion date of February 3, 2025. While the original solicitation was not provided, the award indicates that this is part of a larger Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,431.61, is for the delivery of a specific medical product, the "ZEPBOUND 5 MG/0.5 ML PEN 0.2ML", with a completion date of January 7, 2025. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,143.87, is for the delivery of 4566964401 - ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 17, 2025. This award is not associated with a set-aside designation....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,143.87, is for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a medical product. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and has an ultimate completion date of January 7, 2025. The contract does not have a set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, valued at $1,525.16, for the supply of ZEPBOUND 5 MG/0.5 ML PEN 0.S ML medical products. The contract has an ultimate completion date of January 17, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $25,286.84, is for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.8ML medical products. The contract is a firm fixed-price delivery order with a completion date of February 10, 2025. This award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,994.00, is a Firm Fixed Price Delivery Order for the supply of 4567163949 "ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML" medical products. The contract has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $2,084.34, is for the delivery of ZEPBOUND 10 MG/0.5 ML PEN 0.S ML medical supplies. The contract is a firm fixed-price delivery order with an ultimate completion date of January 13, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB25D2204
    Indefinite Delivery Contract
  • SPE2DB25D2204-SPE2DB25FTGAM
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract award, valued at $8,507.43, is for the delivery of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is February 10, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/9/25, 10:14 AM